Table 5 Completed and ongoing clinical trial of NK cell-based therapy for hematological malignancies

Acute myeloid leukemia

Allogeneic, IL-2 UCB-NK cells

I/II

NCT04347616

Ongoing

Allogeneic NK cell

I

NCT04220684

Ongoing

Alloreactive NK cell

N/A

NCT03955848

Ongoing

Poor prognosis non-AML hematologic malignancies

Allogeneic haploidentical NK cell infusions

I

NCT00697671

Completed

No outcome reported

Refractory non-B lineage hematologic malignancies

Allogeneic haploidentical NK Cell Infusions

I

NCT00640796

Completed

No outcome reported

CD33-positive acute myeloid leukemia

Anti-CD33 CAR-NK cells

I/II

NCT02944162

PMID: 28054442

Found to be effective and prevented both tumor relapses and graft versus host disease

Acute myeloid leukemia & advanced hematological malignancies

Alloreactive, IL-2 activated NK cells

I/II

NCT01220544

Unknown

No outcome reported

Hematological malignancy patients who received fate therapeutics

Genetically modified NK cell

N/A

NCT04093622

Ongoing

High-risk tumor and lymphoma

Allogeneic haploidentical NK cell infusion combined with autologous stem cell transplantation

I

NCT02130869

Completed

No outcome reported

Pediatric acute leukemia

Activated and expanded NK cells (NKAEs)

II

NCT02074657

PMID: 29477379

Found to be safe and feasible

Chronic Lymphocytic Leukemia (CLL)

NK cell with rituximab and Rhu-GMCSF

I

NCT00383994

Completed

No outcome reported

NK cell

I

NCT02280525

Ongoing

CD19 + Leukemia

Allogeneic anti-CD19 CAR-NK cells

I/II

NCT02892695

PMID: 28054442

Found major improvements in treating leukemia

Multiple myeloma

KIR-ligand mismatched NK cells from a haploidentical donor

I

NCT00089453

Completed

No outcome reported

Acute myeloid leukemia & acute lymphoblastic leukemia

Expanded haploidentical NK cells

I

NCT04327037

Ongoing

Ph + acute lymphoblastic leukemia

Autologous NK cell

I

NCT02185781

Unknown

No outcome reported

Lymphoma, myeloma, and leukemia

HLA-I haplotype mismatched NK cell

I

NCT00660166

Completed

No outcome reported

Chronic myeloid leukemia

NK cell

I/II

NCT03348033

Enrolling

B cell non-Hodgkin’s lymphoma

Cord blood-derived expanded allogeneic NK cells combined with rituximab, high-dose chemotherapy, and stem cell transplant

II

NCT03019640

Ongoing

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells combined with high-dose chemotherapy and stem cell transplant

I/II

NCT03579927

Withdrawn

B cell lymphoma

NK cells with rituximab

I/II

NCT02843061

Completed

No outcome reported